India, Oct. 1 -- Lupin announced the launch of Rivaroxaban for Oral Suspension, 1 mg/mL, in the United States. Rivaroxaban for Oral Suspension, 1 mg/mL is bioequivalent to Xarelto' for Oral Suspension, 1 mg/mL of Janssen Pharmaceuticals, Inc.Rivaroxaban for Oral Suspension is indicated for:' Treatment of venous thromboembolism (VTE) and reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years after at least 5 days of initial parenteral anticoagulant treatment.' Treatment of thromboprophylaxis in pediatric patients 2 years and older with congenital heart disease after the Fontan procedure.Rivaroxaban for Oral Suspension, 1 mg/mL (RLD Xarelto') had estimated annual sales of USD 11 million in the U.S. (IQVI...